CellentraTech Files Patent Application Covering A20T013, an αvβ6-Binding Monobody Designed as a Modular Address Ligand for Gene Delivery
CellantraTechTech Announces Discovery and Invention of Novel HPV16 E7-Targeting TCR-T Candidate
Cellantra Announces Discovery and Invention of Novel HPV16 E7-Targeting TCR-T Candidate Read More »
CellantraTechTech Announces Discovery and Invention of Novel HA-2-Targeting TCR-T Candidate for Hematologic Malignancies
CellantraTechTech Announces Discovery and Invention of Novel NY-ESO-1-Targeting TCR Candidate
Cellantra Announces Discovery and Invention of Novel NY-ESO-1-Targeting TCR Candidate Read More »
CellantraTechTech Announces Discovery and Invention of Novel KRAS G12C-Targeting TCR Candidate
Cellantra Announces Discovery and Invention of Novel KRAS G12C-Targeting TCR Candidate Read More »
Cellantra
Announces Discovery and Engineering of Potent HLA-A*11:01-Restricted KRAS G12V TCR Candidate
CellantraTechTech Announces Discovery of Proprietary CardioFibros Target and Biomarker for Precision In Vivo Gene Therapy
CellantraTechTech Announces Discovery of Potent Novel MAGE-C2-Targeting TCR Candidate for Cancer Immunotherapy
CellantraTech AND CAPSTAN SIGN COOPERATION MEMORANDUM TO ADVANCE IN VIVO CAR-T THERAPIES FOR SOLID TUMORS
CellantraTechTech Files Patent Application Covering A20T013, an αvβ6-Binding Monobody Designed as a Modular Address Ligand for Gene Delivery
CellantraTech Therapeutics is a preclinical biotechnology company building a reusable lnps delivery platform and in vivo CAR-T cell therapy.